focus -WSS

focus

author：Wikipedia 2025-10-06 13:32:24 Page View：8

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioAge raises $170M for combination therapy with Zepbound
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

focus

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Let's speed up science by embracing open access publishing

APStockSixyearsago,HarvardscientistJayBradnerdiscoveredsomethingunusual.Hislaboratoryhadisolatedamol

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

For Medicare Advantage, Democrats want stronger protections around AI

Sen.ElizabethWarren(D-Mass.)KentNishimura/GettyImagesSenateDemocratsonThursdaysaidMedicareshouldtake

focus

explore

focus

For Medicare Advantage, Democrats want stronger protections around AI